Scientific Literature Search

Source record

Therapy-resistant symptoms in Parkinson's disease.

Vorovenci RJ, Biundo R, Antonini A.

J Neural Transm (Vienna) · 2015-09-26

DOI: 10.1007/s00702-015-1463-8PMID: 26410626

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Open access

Tonic GABAA Receptors as Potential Target for the Treatment of Temporal Lobe Epilepsy.

Schipper S, Aalbers MW, Rijkers K, Swijsen A, Rigo JM, Hoogland G, Vles JS.

Mol Neurobiol · 2015-09-26

DOI: 10.1007/s12035-015-9423-8PMID: 26409480

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O.

Neurobiol Dis · 2015-09-25

DOI: 10.1016/j.nbd.2015.09.009PMID: 26392287

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling.

Li W, Chen S, Li JY.

Prog Neurobiol · 2015-09-25

DOI: 10.1016/j.pneurobio.2015.09.009PMID: 26408505

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.

Solla P, Cannas A, Marrosu MG, Marrosu F.

Parkinsonism Relat Disord · 2015-09-25

DOI: 10.1016/j.parkreldis.2015.09.039PMID: 26453388

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.

Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, Zhou X, Parker EM, Kennedy ME, Morrow JA.

J Pharmacol Exp Ther · 2015-09-25

DOI: 10.1124/jpet.115.227587PMID: 26407721

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Open access

Mitochondrial dysfunction in psychiatric morbidity: current evidence and therapeutic prospects.

Toker L, Agam G.

Neuropsychiatr Dis Treat · 2015-09-24

DOI: 10.2147/ndt.s70346PMID: 26442764

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Open access

G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease.

Barker RA, Studer L, Cattaneo E, Takahashi J, G-Force PD consortium.

NPJ Parkinsons Dis · 2015-09-24

DOI: 10.1038/npjparkd.2015.17PMID: 28725685

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.

Leveridge M, Collier L, Edge C, Hardwicke P, Leavens B, Ratcliffe S, Rees M, Stasi LP, Nadin A, Reith AD.

J Biomol Screen · 2015-09-24

DOI: 10.1177/1087057115606707PMID: 26403521

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Gait variability in Parkinson's disease: levodopa and walking direction.

Bryant MS, Rintala DH, Hou JG, Collins RL, Protas EJ.

Acta Neurol Scand · 2015-09-23

DOI: 10.1111/ane.12505PMID: 26399376

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease.

Bhidayasiri R, Hattori N, Jeon B, Chen RS, Lee MK, Bajwa JA, Mok VC, Zhang B, Syamsudin T, Tan LC, Jamora RD, Pisarnpong A, Poewe W.

Expert Rev Neurother · 2015-09-21

DOI: 10.1586/14737175.2015.1088783PMID: 26390066

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Source record

Combination therapies: The next logical Step for the treatment of synucleinopathies?

Valera E, Masliah E.

Mov Disord · 2015-09-21

DOI: 10.1002/mds.26428PMID: 26388203

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Article details View source ↗

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

20.509 articles found

Therapy-resistant symptoms in Parkinson's disease.

Tonic GABAA Receptors as Potential Target for the Treatment of Temporal Lobe Epilepsy.

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling.

Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.

Mitochondrial dysfunction in psychiatric morbidity: current evidence and therapeutic prospects.

G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson's disease.

A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.

Gait variability in Parkinson's disease: levodopa and walking direction.

Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease.

Combination therapies: The next logical Step for the treatment of synucleinopathies?

Filters